MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway (Q64067150)
Jump to navigation
Jump to search
scholarly article by Mei Rao et al published 3 May 2019 in Biology Direct
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway |
scholarly article by Mei Rao et al published 3 May 2019 in Biology Direct |
Statements
MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway (English)
0 references
3 May 2019
0 references
14
0 references
1
0 references
9
0 references
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference